Background As a first step towards a vaccine protecting COVID-19 convalescents from
reinfection, we evaluated FINLAY-FR-1A vaccine in a clinical trial. Methods Thirty COVID-19 …

Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …

Objectives To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o)
combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods A …

The zwitterionic Streptococcus pneumoniae serotype 1 polysaccharide (Sp1) is an important
anchor point for our immune system to act against streptococcal infections. Antibodies can …

Background A phase 1, clinical trial to evaluate FINLAY-FR-1A vaccine in COVID-19
convalescent individuals was completed. Here, we report results of the phase 2, clinical trial. …

Background SOBERANA 02 has been evaluated in phase I and IIa studies comparing
homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we …

Background The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the
target for many COVID-19 vaccines. Here we report results for phase I clinical trial of two …

The efficacy of protein and carbohydrate antigens as vaccines can be improved via particulate
delivery strategies. Here, protein and carbohydrate antigens used in formulations of …

Streptococcus pneumoniae is a human pathogen responsible for the majority of childhood
pneumonia and media otitis cases worldwide. The diversity of its capsular polysaccharides (…

We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base
vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity …